News and Trends 12 Dec 2022 Step Pharma announces promising pre-clinical cancer data Step Pharma has announced encouraging pre-clinical data on its first-in-class, highly selective, orally bioavailable CTPS1 inhibitor, STP938. The data were presented at the 64th American Society of Hematology (ASH) annual meeting in New Orleans, Louisiana. The data presented by Step Pharma collaborators demonstrates the potential of STP938, a highly selective CTPS1 inhibitor, as a therapeutic […] December 12, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2022 New biomaterial can regenerate bones and prevent infections Researchers in Spain have developed a new porous material capable of regenerating bones and preventing infections at the same time. The scientists are from the Bioengineering and Biomaterials Laboratory of Universidad Católica de Valencia (UCV) . Tailor-made for each case using 3D printing, the biotech creations contain a bioactive alginate coating. This coating induces bone regeneration […] December 12, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2022 Vevo Therapeutics launches with $12M to ‘discover better drugs’ Vevo Therapeutics, a biotechnology company using its Mosaic in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients, has launched with an oversubscribed and upsized $12 million seed financing round. Wing Venture Capital and General Catalyst co-led the round with participation from Mubadala Capital, AIX Ventures, and Camford […] December 9, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2022 Actinium Pharmaceuticals and Columbia University to study Actimab-A in AML patients Actinium Pharmaceuticals, Inc. has entered into a research collaboration with Columbia University to study Actimab-A, its clinical-stage CD33 targeting radiotherapeutic, with engineered hematopoietic stem cells (eHSCs) modified by CRISPR/Cas9 gene editing technology to knock out CD33 expression. Siddhartha Mukherjee, assistant professor of Medicine at Columbia University Medical Center in the Department of Medicine and Division […] December 9, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2022 Visiox Pharma announces FDA acceptance of glaucoma new drug application Visiox Pharma, LLC has received notification from the U.S. Food and Drug Administration (FDA) that the agency has completed its filing review and accepted for filing the New Drug Application (NDA) for PDP-716 (0.35% brimonidine tartrate) for the treatment of glaucoma. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date […] December 9, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2022 New targeted drug shows benefit against breast cancer in first phase III trial A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial. The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people with advanced forms of the most common type of breast cancer. The findings, presented […] December 9, 2022 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2022 Ginkgo Bioworks launches Ginkgo Enzyme Services Ginkgo Bioworks has announced the launch of Ginkgo Enzyme Services. Ginkgo Enzyme Services is powered by ultra high throughput screening and machine learning-guided protein design, as well as optimized proprietary bacterial and fungal host strains. Ginkgo Enzyme Services solves challenges for R&D teams developing enzymes, from discovery of novel enzyme activity through optimization of enzyme […] December 9, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2022Beyond Biotech podcast 25: Center for Global Development, Humacyte, Transgene This week, we have three interviews. One is from Bio-Europe, a chat with Transgene chief business officer, Steven Bloom, and we also have conversations with Humacyte CEO Laura Niklason, and with Anthony McDonnell, Senior Policy Analyst at the Center for Global Development, on the subject of antimicrobial resistance. We also have our weekly commentary from […] December 9, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2022 The Native Antigen Company expands infectious disease portfolio The Native Antigen Company (part of LGC Clinical Diagnostics), today announced the commercial release of its Sudan Ebolavirus Boniface 1976 Glycoprotein (SEBOV GP). The addition of this latest recombinant protein expands the company’s comprehensive portfolio of antigens and antibodies for infectious diseases and has been designed to support immunoassay and vaccine development. The Native Antigen […] December 9, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 PDC*line Pharma presents first immunological results from trial with PDC*lung01 PDC*line Pharma, a clinical stage biotech company has announced the first immunological results of its PDC-LUNG-101 phase 1/2 clinical trial investigating PDC*Lung01. The company’s lead therapeutic is the off-the-shelf cancer vaccine candidate for non-small cell lung cancer (NSCLC). PDC*line Pharma develops potent and scalable active immunotherapies for cancers. The preliminary data was presented today at […] December 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 8 Dec 2022 Enhertu’s positive results demonstrate improvement in overall survival Enhertu, an antibody drug conjugate, being jointly developed by Daiichi Sankyo and AstraZeneca, has demonstrated a statistically significant and clinically meaningful improvement in overall survival. Updated results from DESTINY-Breast03 phase 3 trial showed Enhertu (trastuzumab deruxtecan) was performing better than trastuzumab emtansine (T-DM1) in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated […] December 8, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 MicrofluidX raises £3.3M to develop advanced therapy manufacturing platform MicrofluidX (MFX), a U.K. based provider of next-generation bioreactors for cell research and manufacturing, has announced £3.3 million ($4 million) of secured investments. This brings the company’s total funding to date to £7 million ($8.5 million). MicrofluidX’s next generation platform, the Cyto Engine, addresses the need for an affordable, scalable cell culture platform to revolutionize […] December 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email